Information  X 
Enter a valid email address

Flying Brands Ltd (FBDU)

  Print      Mail a friend

Monday 02 July, 2018

Flying Brands Ltd

Medimsight and IB Enter into Partnership

RNS Number : 2138T
Flying Brands Limited
02 July 2018
 

 

Medimsight and IB Enter into Partnership

 

Imaging Biometrics®, LLC (IB), a subsidiary of Flying Brands Limited (LON:FBDU) and Medimsight, Ltd have entered into an agreement to provide access to IB's quantitative software solutions via the Medimsight platform. Physicians and researchers can soon purchase the core processing power of IB's FDA cleared technologies securely and efficiently, without the need for any specific IT infrastructure.

 

Medimsight's Artificial Intelligent (AI) marketplace, structured to readily integrate third-party applications, targets four main markets; clinical trials, clinical practice PACS providers, medical researchers, and soon teleradiology. Along with being able to access a variety of proven imaging solutions from a single entry-point, Medimsight offers unlimited storage and free PACS service for those who use it in research, making it ideal for global collaborations and advancing healthcare innovation for both diagnostics, as well as quantitative image analysis and biomarkers.

 

"We are very excited for the integration of IB's solutions in Medimsight. IB is a recognised leader in MR perfusion and diffusion imaging and their applications dovetail perfectly with the overall mission of Medimsight," said Javier González-Zabaleta, CEO of Medimsight.


In addition to neuro applications, specifically, brain tumors and stroke, IB also has whole-body applications that will be integrated within Medimsight. "When coupled with Medimsight's flexible single point of access, IB's automated and quantitative solutions will help clinicians save time and  provide better care for their patients and generate additional revenue for IB" said Michael Schmainda, CEO of IB.

 

ABOUT Medimsight

Medimsight, was born with the vision to become a catalyzer of medical imaging innovation. After years building and facilitating the integration of computer-aided diagnosis tools for research, the company expanded worldwide in 2014 with its cloud marketplace adding deep learning applications, as well as FDA-cleared and CE-marked solutions in early 2018. Thanks to the platform public API, companies can use artificial intelligence tools in a timely manner, including imaging QC and the revolutionary AI imaging triage with precision medicine analytics. For more information about Medimsight, visit the company's website at www.medimsight.com.

 

ABOUT Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of Flying Brands Limited (LON:FBDU), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands Limited

Flying Brands Limited (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel:  020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGRUGUGWMUPRUMP

a d v e r t i s e m e n t